Predictors of biochemical response to somatostatin receptor ligands in acromegaly
Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid))
Martínez-Hernandez, Rebeca (Instituto de Investigación Princesa)
Marques-Pamies, Manuel (Hospital Municipal de Badalona)
Biagetti, Betina (Vall d'Hebron Institut de Recerca (VHIR))
Araujo-Castro, Marta (Hospital Universitario Ramón y Cajal (Madrid))
Puig Domingo, Manuel (Institut Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Ajuts:	Ministerio de Economía y Competitividad PMP15/00027 Instituto de Salud Carlos III PMP22/00021 Instituto de Salud Carlos III PI22/01364
Nota:	This research is supported by grants from the Instituto Carlos III (grants PMP15/00027, co-funded by FEDER; PMP22/00021, funded by the European Union -NextGenerationEU; and FIS PI22/01364, co-funded by the European Union; to MPD).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Publicat a:	Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 38 Núm. 4 (july 2024) , p. 101893, ISSN 1532-1908

DOI: 10.1016/j.beem.2024.101893

19 p, 4.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats